[go: up one dir, main page]

BR9815861A - Composição farmacêutica com revestimento entérico e método de fabricação - Google Patents

Composição farmacêutica com revestimento entérico e método de fabricação

Info

Publication number
BR9815861A
BR9815861A BR9815861-9A BR9815861A BR9815861A BR 9815861 A BR9815861 A BR 9815861A BR 9815861 A BR9815861 A BR 9815861A BR 9815861 A BR9815861 A BR 9815861A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
manufacturing
enteric coating
drug
coating
Prior art date
Application number
BR9815861-9A
Other languages
English (en)
Inventor
Ismat Ullah
Gary J Wiley
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22179393&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9815861(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BR9815861A publication Critical patent/BR9815861A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA COM REVESTIMENTO ENTéRICO E MéTODO DE FABRICAçãO" Uma composição farmacêutica com revestimento entérico contendo alta dosagem de droga é fornecida, incluindo um núcleo que compreende um medicamento que é sensível a um meio com pH abaixo de 3, tal como ddl, cuja composição é preferencialmente na forma de glóbulos, apresentando um revestimento entérico formado de copolímero de ácido metacrílico, plastificante e um revestimento adicional compreendendo um anti-aderente. Os chamados glóbulos apresentam uma exelente resistência a desintegração em pH menor que 3, mas apresentam propriedades excelentes de liberação da droga com pH maior do que 4.5. Um novo método a fabricação da citada composição farmacêutica também é descrito.
BR9815861-9A 1998-05-22 1998-08-04 Composição farmacêutica com revestimento entérico e método de fabricação BR9815861A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8359798A 1998-05-22 1998-05-22
PCT/US1998/016128 WO1999061002A1 (en) 1998-05-22 1998-08-04 Enteric coated pharmaceutical composition and method of manufacturing

Publications (1)

Publication Number Publication Date
BR9815861A true BR9815861A (pt) 2001-01-16

Family

ID=22179393

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9815861-9A BR9815861A (pt) 1998-05-22 1998-08-04 Composição farmacêutica com revestimento entérico e método de fabricação

Country Status (40)

Country Link
US (2) US6224910B1 (pt)
EP (1) EP1079809B1 (pt)
JP (2) JP3798625B2 (pt)
KR (1) KR100484299B1 (pt)
CN (1) CN1149075C (pt)
AP (1) AP1206A (pt)
AR (1) AR017747A1 (pt)
AT (2) ATE311859T1 (pt)
AU (1) AU750911B2 (pt)
BG (1) BG65398B1 (pt)
BR (1) BR9815861A (pt)
CA (1) CA2332922C (pt)
CO (1) CO5070679A1 (pt)
CY (1) CY1119543T1 (pt)
CZ (1) CZ300497B6 (pt)
DE (2) DE1079809T1 (pt)
DK (2) DK1079809T3 (pt)
DZ (1) DZ2797A1 (pt)
EE (1) EE04926B1 (pt)
ES (1) ES2165833T3 (pt)
GE (1) GEP20033014B (pt)
HK (1) HK1034461A1 (pt)
HU (1) HU226491B1 (pt)
ID (1) ID27031A (pt)
IL (1) IL139274A (pt)
LT (1) LT4843B (pt)
LV (1) LV12602B (pt)
MA (1) MA26636A1 (pt)
NO (2) NO322903B1 (pt)
NZ (1) NZ508194A (pt)
OA (1) OA11512A (pt)
PL (1) PL193294B1 (pt)
RO (1) RO121674B1 (pt)
RU (1) RU2197227C2 (pt)
SK (1) SK284890B6 (pt)
TN (1) TNSN99097A1 (pt)
TR (1) TR200003373T2 (pt)
UA (1) UA69413C2 (pt)
WO (1) WO1999061002A1 (pt)
ZA (1) ZA993090B (pt)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8828432B2 (en) 1996-10-28 2014-09-09 General Mills, Inc. Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles
JP2002507399A (ja) 1998-03-23 2002-03-12 ゼネラル ミルズ インコーポレイテッド 可食性製品への成分のカプセル化
US7122207B2 (en) 1998-05-22 2006-10-17 Bristol-Myers Squibb Company High drug load acid labile pharmaceutical composition
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
SE9802973D0 (sv) 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
US6436453B1 (en) 2000-06-16 2002-08-20 General Mills, Inc. Production of oil encapsulated minerals and vitamins in a glassy matrix
US6468568B1 (en) 2000-06-16 2002-10-22 General Mills, Inc. Oligosaccharide encapsulated mineral and vitamin ingredients
BR0115206A (pt) * 2000-11-10 2003-10-07 Hoffmann La Roche Composições hidroliticamente instáveis
EP1380330B1 (en) * 2001-04-04 2008-06-04 Ngk Insulators, Ltd. Rain water treating device in combined sewage, and backwashing method therefor
US8658202B2 (en) 2001-04-25 2014-02-25 Western University Of Health Sciences Coated drug delivery formulations
US6759058B1 (en) * 2001-04-25 2004-07-06 Western Center For Drug Development College Of Pharmacy Western University Of Health Sciences Enteric-coated proliposomal formulations for poorly water soluble drugs
MXPA04002891A (es) * 2001-09-28 2005-06-20 Johnson & Johnson Composicion farmaceutica a base de pasta de azucar.
US6967218B2 (en) 2002-01-11 2005-11-22 Biovail Laboratories, Inc. Pravastatin pharmaceutical formulations and methods of their use
EP1905431A1 (en) * 2002-01-11 2008-04-02 Circ Pharma Research and Development Limited Pravastatin pharmaceutical formulations and methods of their use
WO2003061688A1 (fr) * 2002-01-21 2003-07-31 Nrl Pharma, Inc. Nouveaux analgesiques
WO2003080026A1 (en) * 2002-03-22 2003-10-02 Ranbaxy Laboratories Limited Controlled release drug delivery system of pravastatin
US20040028737A1 (en) * 2002-08-12 2004-02-12 Kopran Research Laboratories Limited Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same
EP2033631A3 (en) * 2002-09-03 2009-06-03 Circ Pharma Research and Development Limited Pravastatin pharmaceutical formulations and methods of their use
AU2003263556A1 (en) * 2002-09-03 2004-03-29 Circ Pharma Research And Development Limited Pharmaceuticals formulations and methods for modified release of statin drugs
BRPI0408999A (pt) * 2003-04-04 2006-03-28 Pharmacia Corp comprimidos prensados de multiparticulados de liberação oral prolongada
CN100415211C (zh) * 2003-07-03 2008-09-03 上海现代药物制剂工程研究中心 抗艾滋病药去羟肌苷的肠溶微粒组合物及制备方法
AU2004296877A1 (en) * 2003-12-09 2005-06-23 Incyte Corporation Dosing methods for ss-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine antiviral therapy
DE602005009677D1 (de) * 2004-03-22 2008-10-23 Solvay Pharm Gmbh Orale pharmazeutische zusammensetzungen von produkten mit lipase, insbesondere von pankreatin, mit tensiden
US20050281876A1 (en) 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
TW200631609A (en) * 2004-11-18 2006-09-16 Bristol Myers Squibb Co Enteric coated bead comprising ixabepilone, and preparation and administration thereof
EP1824458A1 (en) * 2004-11-18 2007-08-29 Bristol-Myers Squibb Company Enteric coated bead comprising epothilone or an epothilone analog, and preparation and administration thereof
WO2006054175A2 (en) * 2004-11-18 2006-05-26 Aurobindo Pharma Limited Stable dosage forms of acid labile drug
US8673352B2 (en) * 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
PL1916995T5 (pl) 2005-07-29 2022-10-31 Stichting Groningen Centre For Drug Research Kontrolowany wartością ph impulsowy układ podawczy, sposoby przygotowania i zastosowanie
PL2278002T3 (pl) 2005-07-29 2017-12-29 Abbott Laboratories Gmbh Pankreatyna o zmniejszonej zawartości wirusowej
WO2007020259A2 (en) 2005-08-15 2007-02-22 Solvay Pharmaceuticals Gmbh Controlled release pharmaceutical compositions for acid labile drugs
US9198871B2 (en) * 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US11266607B2 (en) * 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US7803413B2 (en) 2005-10-31 2010-09-28 General Mills Ip Holdings Ii, Llc. Encapsulation of readily oxidizable components
WO2007072060A2 (en) * 2005-12-23 2007-06-28 Cipla Limited Particles comprising a core containing a hmg-coa reductase inhibitor and coated with a film
US8026284B2 (en) 2006-01-27 2011-09-27 The Regents Of The University Of California Enterically coated cystamine, cysteamine and derivatives thereof
WO2007109244A2 (en) * 2006-03-21 2007-09-27 Morehouse School Of Medicine Novel nanoparticles for delivery of active agents
US10072256B2 (en) * 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
ES2331501B1 (es) * 2007-11-14 2010-10-21 Blanver Farmoquimica, Ltda Composicion farmaceutica solida de didanosina.
US20090130063A1 (en) * 2007-11-15 2009-05-21 Solvay Pharmaceuticals Gmbh Process for separating and determining the viral load in a pancreatin sample
MX2010011209A (es) 2008-04-24 2010-11-12 Squibb Bristol Myers Co Uso de epotilona d en el tratamiento de enfermedades asociadas a tau incluyendo enfermedad de alzheimer.
AU2009322285B2 (en) * 2008-12-03 2016-07-28 Bausch Health Ireland Limited Formulations of guanylate cyclase C agonists and methods of use
US20110142889A1 (en) * 2009-12-16 2011-06-16 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
JP6393037B2 (ja) 2010-09-15 2018-09-19 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃアゴニストの製剤および使用方法
GB2484929A (en) 2010-10-25 2012-05-02 Maria Christiana Peter Geraedts An edible product including plant protein
KR20120135063A (ko) * 2011-06-01 2012-12-12 닛토덴코 가부시키가이샤 입자 제제 및 그 제조 방법
US10117447B1 (en) * 2013-03-15 2018-11-06 The United States Of America, As Represented By The Secretary Of Agriculture Extrusion of high density hydroxypropylmethylcellulose edible flexible gels
TWI649100B (zh) 2013-06-17 2019-02-01 地平線罕見醫學製藥有限責任公司 延遲釋放型半胱胺珠粒調配物，以及其製備及使用方法
CN104758180A (zh) * 2014-01-06 2015-07-08 山东诚创医药技术开发有限公司 一种复方制剂胶囊的二次填充方法
US10058542B1 (en) 2014-09-12 2018-08-28 Thioredoxin Systems Ab Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith
UA125747C2 (uk) 2015-09-01 2022-06-01 Фьост Вейв Байо, Інк. Способи та композиції для лікування станів, пов'язаних із аномальною запальною відповіддю
US10143665B2 (en) 2015-11-17 2018-12-04 Horizon Orphan Llc Methods for storing cysteamine formulations and related methods of treatment
US10588864B2 (en) 2016-03-11 2020-03-17 Gateway Pharmaceuticals LLC Pharmaceutical compositions for colon-specific delivery
RU2670447C2 (ru) * 2016-11-17 2018-10-23 Общество с ограниченной ответственностью "Изварино Фарма" Пероральная твердая лекарственная форма с микофенольной кислотой или ее солью для использования в качестве иммунодепрессанта для лечения или предупреждения отторжения трансплантата органа или ткани и способ ее получения
EP3630171A1 (en) 2017-05-26 2020-04-08 Animal Microbiome Analytics, Inc. Products and methods for therapeutic administration of microorganisms to non-human animals
KR20210043779A (ko) * 2019-10-11 2021-04-22 넨시스(주) 판크레아틴 장용코팅 펠릿 제조방법
US20230102999A1 (en) 2020-01-10 2023-03-30 First Wave Bio, Inc. Deuterated niclosamide
US10980756B1 (en) 2020-03-16 2021-04-20 First Wave Bio, Inc. Methods of treatment
US20230190684A1 (en) 2020-03-16 2023-06-22 First Wave Bio, Inc. Methods of treating covid-19 with a niclosamide compound

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2809918A (en) 1955-10-17 1957-10-15 Victor M Hermelin Sustained release pharmaceutical preparations
DE2010416B2 (de) 1970-03-05 1979-03-29 Hoechst Ag, 6000 Frankfurt Oral anwendbare Arzneiform mit Retardwirkung
FR2471186A1 (fr) 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
ZA822995B (en) 1981-05-21 1983-12-28 Wyeth John & Brother Ltd Slow release pharmaceutical composition
US4704295A (en) 1983-09-19 1987-11-03 Colorcon, Inc. Enteric film-coating compositions
US4556552A (en) 1983-09-19 1985-12-03 Colorcon, Inc. Enteric film-coating compositions
US4728512A (en) 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
JPS62501712A (ja) 1985-08-26 1987-07-09 アメリカ合衆国 ２′、３′―ジデオキシイノシン、２′，３′―ジデオキシグアノシンまたは２′，３′―ジデオキシアデノシンを含有する抗ｈｔｌｖ―３／ｌａｖ剤
US5254539A (en) 1985-08-26 1993-10-19 U.S. Government, Dept. Of Health And Human Services, C/O National Institutes Of Health Method of treating HIV with 2',3'-dideoxyinosine
US4975283A (en) 1985-12-12 1990-12-04 Bristol-Myers Squibb Company Stabilized enteric coated aspirin granules and process for preparation
US4775536A (en) 1986-02-24 1988-10-04 Bristol-Myers Company Enteric coated tablet and process for making
US4794001A (en) 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
GB8618811D0 (en) * 1986-08-01 1986-09-10 Approved Prescription Services Sustained release ibuprofen formulation
WO1988002629A1 (en) * 1986-10-16 1988-04-21 American Health Products Corporation 2',3'-didesoxyadenosine composition
US5026560A (en) 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
SE460946B (sv) * 1987-03-16 1989-12-11 Lejus Medical Ab En multipel-unit-dos komposition av kinidinglukonat
US4808413A (en) 1987-04-28 1989-02-28 E. R. Squibb & Sons, Inc. Pharmaceutical compositions in the form of beadlets and method
US5049394A (en) * 1987-09-11 1991-09-17 E. R. Squibb & Sons, Inc. Pharmaceutical composition containing high drug load and method for preparing same
JP2643222B2 (ja) 1988-02-03 1997-08-20 エーザイ株式会社 多重層顆粒
US4925675A (en) 1988-08-19 1990-05-15 Himedics, Inc. Erythromycin microencapsulated granules
US5026559A (en) 1989-04-03 1991-06-25 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
PH30058A (en) * 1989-11-24 1996-11-08 Biochemie Gmbh Pancreation preparations
US5158777A (en) * 1990-02-16 1992-10-27 E. R. Squibb & Sons, Inc. Captopril formulation providing increased duration of activity
US5175003A (en) 1990-04-06 1992-12-29 Biosytes Usa, Inc. Dual mechanism controlled release system for drug dosage forms
US5556839A (en) * 1991-04-29 1996-09-17 Eli Lilly And Company Form II Dirithromycin
NZ243567A (en) * 1991-07-22 1995-04-27 Bristol Myers Squibb Co Pharmaceutical oral formulation of a dideoxy purine nucleoside comprising the nucleoside together with a water-insoluble antacid buffering composition
US5326570A (en) * 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
US5225202A (en) * 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
US5350584A (en) 1992-06-26 1994-09-27 Merck & Co., Inc. Spheronization process using charged resins
SG42869A1 (en) 1992-08-05 1997-10-17 Faulding F H & Co Ltd Pelletised pharmaceutical composition
JPH0710747A (ja) * 1993-04-28 1995-01-13 Takeda Chem Ind Ltd 固形製剤およびその製造方法
IT1265074B1 (it) * 1993-05-18 1996-10-30 Istituto Biochimico Italiano Composizione farmaceutica a lento rilascio contenente come sostanza attiva un acido biliare
US5536507A (en) 1994-06-24 1996-07-16 Bristol-Myers Squibb Company Colonic drug delivery system
EP0689840A1 (de) * 1994-06-28 1996-01-03 Spirig Ag Pharmazeutische Präparate Neues orales Erythromycinbase enthaltendes Arzneimittel
US5733575A (en) 1994-10-07 1998-03-31 Bpsi Holdings, Inc. Enteric film coating compositions, method of coating therewith, and coated forms
US5686106A (en) 1995-05-17 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form for colonic delivery
SG80553A1 (en) 1995-07-20 2001-05-22 Tanabe Seiyaku Co Pharmaceutical preparation in form of coated capsule releasable at lower part of digestive tract
US5789014A (en) 1995-12-25 1998-08-04 Shin-Etsu Chemical Co., Ltd. Method of manufacturing a solid preparation coated with non-solvent coating
SE9600071D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I

Also Published As

Publication number Publication date
WO1999061002A1 (en) 1999-12-02
DE69832731T2 (de) 2006-09-14
ATE311859T1 (de) 2005-12-15
NO322903B1 (no) 2006-12-18
NO20062106L (no) 1999-11-23
CA2332922A1 (en) 1999-12-02
EP1079809A4 (en) 2001-11-07
LT4843B (lt) 2001-09-25
CN1294509A (zh) 2001-05-09
AU750911B2 (en) 2002-08-01
TR200003373T2 (tr) 2001-03-21
CZ300497B6 (cs) 2009-06-03
AR017747A1 (es) 2001-10-24
ES2165833T1 (es) 2002-04-01
US6224910B1 (en) 2001-05-01
HUP0101714A2 (hu) 2002-01-28
TNSN99097A1 (fr) 2005-11-10
NO20005879D0 (no) 2000-11-21
CY1119543T1 (el) 2018-04-04
JP2006022115A (ja) 2006-01-26
DK1079809T3 (da) 2006-02-20
LV12602B (en) 2001-07-20
PL193294B1 (pl) 2007-01-31
JP2002516268A (ja) 2002-06-04
IL139274A0 (en) 2001-11-25
NZ508194A (en) 2003-07-25
SK284890B6 (sk) 2006-02-02
MA26636A1 (fr) 2004-12-20
KR100484299B1 (ko) 2005-04-20
AP1206A (en) 2003-09-18
IL139274A (en) 2004-12-15
CA2332922C (en) 2008-02-12
AT6311U1 (de) 2003-08-25
DE1079809T1 (de) 2002-08-22
LT2000105A (lt) 2001-04-25
NO20005879L (no) 2001-01-18
ES2165833T3 (es) 2006-05-16
ID27031A (id) 2001-02-22
AU8685498A (en) 1999-12-13
EP1079809A1 (en) 2001-03-07
HK1034461A1 (en) 2001-10-26
US20010005716A1 (en) 2001-06-28
SK16302000A3 (sk) 2001-08-06
DZ2797A1 (fr) 2003-12-01
GEP20033014B (en) 2003-07-25
EE200000680A (et) 2002-10-15
BG65398B1 (bg) 2008-06-30
RO121674B1 (ro) 2008-02-28
EP1079809B1 (en) 2005-12-07
RU2197227C2 (ru) 2003-01-27
OA11512A (en) 2004-02-03
ZA993090B (en) 2000-11-06
AP2000001988A0 (en) 2000-12-31
EE04926B1 (et) 2007-12-17
DE69832731D1 (de) 2006-01-12
JP3798625B2 (ja) 2006-07-19
HUP0101714A3 (en) 2002-10-28
LV12602A (en) 2001-01-20
UA69413C2 (uk) 2004-09-15
PL344259A1 (en) 2001-10-22
HU226491B1 (en) 2009-03-02
CN1149075C (zh) 2004-05-12
DK200200229U3 (da) 2003-01-24
CO5070679A1 (es) 2001-08-28
BG105061A (bg) 2001-07-31
KR20010043736A (ko) 2001-05-25
CZ20004362A3 (en) 2001-05-16

Similar Documents

Publication Publication Date Title
BR9815861A (pt) Composição farmacêutica com revestimento entérico e método de fabricação
BR9815948A (pt) Tablete farmacêutico revestindo entérico e processo de manufatura
MXPA05008033A (es) Composiciones de milnacipran en forma de multiparticulas para administracion oral.
DK0825858T3 (da) Flerumættede omega-3-fedtsyrer til behandling af inflammatorisk tarmsygdom i kapsler med tidsafhængig frigivelse
YU31599A (sh) Brzo oslobadjajući i za ukus maskirajući farmaceutski oblik doze
ATE380022T1 (de) Multipartikuläre arzneiform, enthaltend mindestens zwei unterschiedlich überzogene pelletformen
BE901359A (fr) Composition pharmaceutique a absorption reglee.
BR0317275A (pt) Liberação controlada de uma substância ativa em um ambiente de gordura alta
KR920002135A (ko) 대장에서만 방출할수 있는 피복시킨 고체 약물형태
RU99108461A (ru) Лекарственная форма для перорального введения с отложенным немедленным высвобождением и способ ее приготовления
KR950005301A (ko) 방출 개시 제어 및 방출 속도 제어형 제제
ATE29107T1 (de) Waessrig-alkoholische dispersionen von phempfindlichen polymeren und weichmachern, verfahren zu deren herstellung und eine fest orale medizinische verabreichungsform, die eine daraus hergestellte enterische schicht enthaelt.
MX9402938A (es) Composicion terapeutica que comprende nicotinamida-adenina-dinucleotido ynicotinamida-adenina-fosfato-dinucleotido, estable ingerible y absorbible.
BR9903345A (pt) Emplastro cosmético, farmacêutico ou dermatológico e conjunto
KR870000069A (ko) 안정한 고체 제형의 제조 방법
DE60126433D1 (de) Prozess zur herstellung von pharmazeutischen zusammensetzungen zur verwendung mit weichgelatine formulierungen
KR860000865A (ko) 약제 제형의 제조방법
KR950031052A (ko) 알푸조신 히드로클로라이드의 서방성 투약형태
DK0856312T3 (da) Anvendelse af trospiumchlorid til fremstilling af et lægemiddel til behandling af blæresygdomme
EA200300110A1 (ru) Композиция элетриптана в виде частиц
CO5580800A2 (es) Composicion de una preparacion que contiene un compuesto fisiologicamente activo inestable en acido, y un proceso para producirlo
ES2052816T3 (es) Una composicion para revestir granulos de farmacos.
CA2374039A1 (en) Multiparticulate controlled release selective serotonin reuptake inhibitor formulations
BR0206979A (pt) Métodos e composições para reduzir o paladar de agentes farmaceuticamente ativos
KR970703774A (ko) 활성물질 방출이 지연된 카바마제핀 약제(Carbamazepine medicament with retarded active substance release)

Legal Events

Date Code Title Description
FB36 Technical and formal requirements: requirement - article 36 of industrial property law
HJEG Technical examination (opinion): technical examination (opinion) related to article 229 of industrial property law
FF Decision: intention to grant
FG9A Patent or certificate of addition granted
B24B Patent annual fee: requirement for complementing annual fee
B24D Patent annual fee: restoration after fee payment
B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 04.08.2018